| Document |
Document Title |
|
WO/2023/086929A1 |
The present disclosure relates, in part, to compositions and methods, including chimeric proteins, that find use in the treatment of disease, such as immunotherapies for cancer.
|
|
WO/2023/086900A1 |
The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Αβ) and/or Tau. In certain embodiments, the CARs do not comprise an intracellular domain. Methods of treat...
|
|
WO/2023/083243A1 |
The present invention relates to the technical field of fusion proteins, and relates in particular to an anti-IL-17/VEGF bifunctional fusion protein and a use thereof. The anti-IL-17/VEGF bifunctional fusion protein comprises an anti-IL-...
|
|
WO/2023/082022A1 |
There is described herein polyvalent HCV vaccines, preferably comprising SEQ ID Nos. 1-5. There is also described herein methods of designing polyvalent vaccines.
|
|
WO/2023/081959A1 |
An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises one or more immunoglobulin heavy chain polypeptide comprising an Fc region component comprising at leas...
|
|
WO/2023/083379A1 |
The present invention relates to a fusion protein construct taking interleukin 15 as an active ingredient and the use thereof. Specifically, the fusion protein construct comprises: (1) a first structural unit: an α subunit sushi domain ...
|
|
WO/2023/083250A1 |
Provided herein are genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD2, and methods of use thereof.
|
|
WO/2023/086896A1 |
Disclosed is a method of treating a subject having a malignant glioma comprising: administering by convection-enhanced delivery (CED) for a period of up to 96 hours a therapeutically effective amount of a mutagenized IL13 linked to a cyt...
|
|
WO/2023/078438A1 |
A mycobacterium tuberculosis (MTB) fusion protein, a preparation method therefor and a use thereof. The MTB fusion protein is composed of two proteins, EAST6 and CFP10, has six connection structures, namely EEC, ECE, CEE, ECC, CEC and CC...
|
|
WO/2023/078245A1 |
Provided are an IL-10 monomer fusion protein and a use thereof, which relate to the field of biomedicine. The fusion protein comprises an antibody and an IL-10 monomer. The fusion protein of the present invention has a relatively strong ...
|
|
WO/2023/077943A1 |
Provided are a bispecific chimeric antigen receptor targeting an HIV-1 envelope protein. The chimeric antigen receptor comprises: (1) a recognition unit targeting an HIV-1gp120 protein co-receptor binding site; (2) a recognition unit tar...
|
|
WO/2023/077206A1 |
This invention consists of genetically modified epitopes and multiepitope proteins composed of these genetically modified epitopes to avoid the formation of neoepitopes. The multiAAA protein is composed of genetically modified epitopes b...
|
|
WO/2023/077210A1 |
Generally, the present disclosure provides novel bacterial translocation domains for use in cellular delivery. An example is the translocation domain from the Austwickia chelonae protein of SEQ ID NO:2, the translocation domain having th...
|
|
WO/2023/077924A1 |
An anti-tumor fusion protein, wherein the fusion protein can inhibit the growth of MUC1-positive tumor cells, and can inhibit the growth of pancreatic cancer tumor cells. The fusion protein has broad application prospects for the prevent...
|
|
WO/2023/081754A1 |
Disclosed are cluster CAR and therapeutic payload nucleic acids, immune cells containing them, and uses thereof for controllable adoptive cell therapy and killing CAR T-cell resistant tumor cells.
|
|
WO/2023/079141A2 |
Infarction damage is ameliorated or treated through the administration of a mitochondrial degradation inhibitor, such as one that acts by inhibiting translocation of one or more molecules across a mitochondrial membrane, for example BAX/...
|
|
WO/2023/077287A1 |
The present invention provides vNAR single domain antibodies and the use thereof. The vNAR single domain antibodies according to the present invention has high affinity to EGFP and/or SARS-COV-2. Also provided are biparatopic vNAR single...
|
|
WO/2023/081861A1 |
Provided are expression cassettes that include coding sequences encoding at least one polar amino acid or at least one expression enhancement peptide that includes one or more polar amino acids, a polypeptide of interest, and a bacterial...
|
|
WO/2023/081783A1 |
Provided are high-throughput screens for biologically active modulators of a target enzyme that mimic or recreate natural processes of diversification and selection. In some embodiments, the platform comprises one or more expression syst...
|
|
WO/2023/078425A1 |
The invention provides a safe and efficient method for in vitro transduction of double-negative T cells (DNT), and cells prepared using the method, and a preparation containing the cells. In the present invention, under the condition tha...
|
|
WO/2023/078431A1 |
A synthetic T cell receptor and antigen receptor specifically binding to mesothelin and the use thereof. TCR and CAR are modified with an antigen-binding fragment targeting MSLN, which results in a better tumor treatment effect.
|
|
WO/2023/070353A1 |
Provided herein are antibodies, masked antibodies (e.g., activatable antibodies), and antigen-binding fragments that target human CD47, polynucleotides encoding the same, therapeutic compositions thereof, and their use to treat CD47-posi...
|
|
WO/2023/071987A1 |
The present invention relates to the technical field of biological pharmacy, and in particular to an anti-HER2 immunotoxin molecule and a preparation method therefor and an application thereof. The anti-HER2 immunotoxin molecule comprise...
|
|
WO/2023/072213A1 |
A PD-L1 binding molecule and an application thereof, relating to the technical field of monoclonal antibodies. Provided are a preparation method for the PD-L1 binding molecule, a use of the PD-L1 binding molecule, and a kit, immune conju...
|
|
WO/2023/070527A1 |
A condition-controlled spliceable chimeric antigen receptor molecule and an application thereof. The spliceable chimeric antigen receptor molecule comprises an antigen recognition unit and a signal transduction unit; the antigen recognit...
|
|
WO/2023/072182A1 |
Provided are anti-IL-36R antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.
|
|
WO/2023/072145A1 |
A method for purifying single-stranded DNA is provided. The method can comprise: mixing a sample containing single-stranded DNA with a single-stranded DNA binding protein, and incubating for a first time period to obtain a first product,...
|
|
WO/2023/072177A1 |
Provided herein are antibodies, masked antibodies (e.g., activatable antibodies), and antigen-binding fragments that target human CD47, polynucleotides encoding the same, therapeutic compositions thereof, and their use to treat CD47-posi...
|
|
WO/2023/072103A1 |
Provided is an allogeneic immune cell, from a donor, which is capable of recognizing an autoantigen of a subject, wherein the subject and the donor have at least one same allele at HLA-A, HLA-B and HLA-C loci, respectively. Further provi...
|
|
WO/2023/070815A1 |
The present invention is suitable for the field of antitumor drugs. Provided is a method for inducing the sumoylation of G1/S-specific cyclin-D1. The environment where the G1/S-specific cyclin-D1 is present contains SUMO protein, and the...
|
|
WO/2023/071267A1 |
Disclosed in the present invention are a protein complex based on DNases of a colicin E family and an application thereof in an artificial protein scaffold. The protein complex comprises any one or more of an interaction pair formed by a...
|
|
WO/2023/077032A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cu...
|
|
WO/2023/077026A1 |
Disclosed herein are methods of culturing immune cells in a medium comprising at least about 5 mM potassium ion, wherein the medium is capable of increasing the stemness of the immune cells. In some aspects, the immune cells which are cu...
|
|
WO/2023/065046A1 |
Herein in provided a recombinant polypeptide comprising a polypeptide for preventing or reducing interaction between the human proteins EAG2 and Kvß2, and a cell-penetrating peptide. The polypeptide may comprise a portion of Kvß2 from ...
|
|
WO/2023/065700A1 |
Provided herein are a growth hormone fusion protein and its use thereof. The fusion protein comprises an Fc mutant, wherein the Fc mutant comprises the first peptide chain, wherein the first peptide chain 1) comprises mutantions at the f...
|
|
WO/2023/068328A1 |
The purpose of the present invention is to discover and provide a novel ubiquitin drug discovery technique whereby it becomes possible to induce a ubiquitin-proteasome system from a target peptide that is difficult to be ubiquitinated an...
|
|
WO/2023/066133A1 |
The present invention relates to nanobodies that specifically bind to MSLN or antigen-binding fragments thereof, a composition containing the nanobodies or antigen-binding fragments thereof, a nucleic acid encoding the antibodies or anti...
|
|
WO/2023/068327A1 |
The present invention addresses the problem of: providing a method for reliably chemogenetically controlling the activity of a protein, and providing a protein used in this method. Specifically, the present invention is a plurality of pr...
|
|
WO/2023/065017A1 |
The present description relates to a conjugated compound an antibody covalently linked to enhancer moiety composed by a nuclear localization sequence (NLS), covalently linked to a sterol variant, such as cholic acid (ChAc) or a variant t...
|
|
WO/2023/068226A1 |
The present invention provides: an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma; an antibody-drug conjugate that contains said antibody; a pharmaceutical composition that employs said an...
|
|
WO/2023/060420A1 |
The present invention provides a mutant of a porin monomer, a protein pore containing same, and a use thereof for detecting a target analyte. The amino acid of the mutant of the porin monomer comprises a sequence shown in SEQ ID NO:1, an...
|
|
WO/2023/061502A1 |
A bispecific binding molecule having high selectivity for Kv1.3 but different affinity for integrin β7, a pharmaceutical composition thereof, and a use thereof. The bispecific binding molecule is formed by the fusion of a toxin polypept...
|
|
WO/2023/060922A1 |
Provided are an antibody specifically binding to CD276 or an antigen-binding fragment thereof, and a preparation method therefor, which can be used to prepare immune effector cells targeting CD276, and provide a way to treat or improve d...
|
|
WO/2023/064793A1 |
Provided herein are fusion proteins comprising (i) interleukin 7 (IL-7) or an IL-7 variant and (ii) IL-21 or and IL-21 variant. Also provided herein are nucleic acids encoding a. fusion protein comprising (i) IL-7 or an IL-7 variant and ...
|
|
WO/2023/062604A1 |
The disclosure provides chimeric antigen receptors and antibodies that comprise antigen-binding domains that specifically bind human STEAP2, nucleotides that encode the same, cells comprising the same, and methods of using the same in th...
|
|
WO/2023/064937A1 |
Described herein are RNA sequence (including siRNA, shRNA, and/or mRNA) carrier platforms for rapid and targeted delivery of siRNAs, shRNAs, and/or mRNAs into cytoplasm of tumor cells, to induce a tumor killing effect. Also described her...
|
|
WO/2023/061487A1 |
The present invention relates to a polypeptide for inhibiting TRPM8 and a use thereof. Specifically, the present invention provides a polypeptide or a pharmaceutically acceptable salt thereof; the polypeptide of the present invention has...
|
|
WO/2023/060358A1 |
A fusion protein comprises a nanocage monomer or subunit thereof linked to an Fc polypeptide, wherein the Fc polypeptide comprises an IgG4 Fc chain with a mutation at one or more of positions 228, 234, 235, 237, and 238, according to EU ...
|
|
WO/2023/061005A1 |
Provided is a novel antibody-cytokine fusion protein. Further provided are a bispecific molecule and an immunoconjugate comprising the antibody-cytokine fusion protein, as well as a nucleic acid molecule encoding the antibody-cytokine fu...
|
|
WO/2023/060359A1 |
A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit th...
|
